Patient heal thyself: Solution to treatment for chronic infections could lie in patient's blood

This discovery gives hope for a more effective and cheaper treatment strategy to millions worldwide suffering from chronic infections

2013-09-23

(Press-News.org) 1. A recent discovery by scientists at A*STAR's Singapore Institute for Clinical Sciences (SICS), in close collaboration with researchers at the Singapore Immunology Network (SIgN), provides hope for a new personalised treatment strategy that could use a patient's own blood to treat the infection. This could help treat millions of people living with chronic infections such as HIV, Hepatitis B or Hepatitis C. These findings were published in the August 2013 issue of The Journal of Clinical Investigation.

2. Patients suffering from chronic infections often have to undergo long periods of anti-viral drug therapy to control the virus. Anti-viral drugs are not fully effective against viruses such as Hepatitis B and Hepatitis C, which have chronically-infected about 400 million worldwide with more than 1,000,000 people dying from Hepatitis-related diseases every year.

3. Vaccines are a potentially effective means to treat chronic viral infections such as this because they can eliminate the virus naturally. However, vaccines for patients with chronic infections are often difficult to produce since these patients already have weak immune responses or the vaccine is not effective due to genetic diversity amongst viruses.

4. The team at SICS led by Prof Antonio Bertoletti has discovered that monocytes, a type of white blood cell that can activate an immune response, are able to capture the virus in chronically-infected patients and use the captured virus to boost the patient's own immune response.

5. By using the viral antigen already present in the blood of the patient suffering from a chronic illness, this strategy redefines therapeutic vaccines by cutting down on time and resources as there is no need to specially isolate the viral proteins from patients, purify it, and then inactivate it to create a vaccine.

6. All the proteins present within the virus can be used to create a personalised vaccine for each individual. This also means that many of the complex issues associated with current vaccine therapy against chronic infections can be overcome, such as that of genetic diversity of viruses.

7. One of the greatest beneficiaries of this discovery would be chronically-infected patient populations in lower socio-economic strata. By tailoring vaccines to be more specific to each virus and each patient, vaccine production can be simplified and thus less costly. Vaccines produced via this discovery could improve the accessibility of such treatments.

8. Prof Bertoletti said, "Mobilizing the immune system to use the virus within the patient for a vaccine is a simple idea that could lead to a personalised, yet widely applicable, vaccine for chronic infections."

9. Prof Judith Swain, Executive Director of SICS said, "This excellent collaborative discovery between SICS and SIgN is a milestone in vaccine therapy for chronic infections. I believe that these findings will go a long way in improving future therapeutic treatments for chronic infections." ### Notes for Editor: The research findings described in this media release can be found in the August 2013 online issue of The Journal of Clinical Investigation under the title, "Mobilizing monocytes to cross-present circulating viral antigen in chronic infection" by Adam J. Gehring1, Muzlifah Haniffa2,3, Patrick Kennedy4, Zi Zong Ho1, Carolina Boni5, Amanda Shin3, Nasirah Banu1, Adeline Chia1, Seng Gee Lim6, Carlo Ferrari5, Florent Ginhoux3, and Antonio Bertoletti1,7,8

1 Infection and Immunity Programme, Singapore Institute for Clinical Sciences, Agency for Science Technology and Research (A*STAR), Singapore.
2 Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom.
3 Singapore Immunology Network, Agency for Science Technology and Research (A*STAR), Singapore.
4 Center for Digestive Disease, Blizard Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, London, United Kingdom.
5 Unit of Infectious Diseases and Hepatology, Laboratory of Viral Immunopathology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
6 Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
7 Program Emerging Viral Diseases, Duke-NUS Graduate Medical School, Singapore.
8 Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) For media queries and clarifications, please contact:

Vithya Selvam (Ms)
Corporate Communications
Agency for Science, Technology and Research
Tel: (+65) 6826 6291
Email: vithya_selvam@a-star.edu.sg About the Agency for Science, Technology and Research (A*STAR) The Agency for Science, Technology and Research (A*STAR) is the lead agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. A*STAR oversees 14 biomedical sciences and physical sciences and engineering research institutes, and six consortia & centres, located in Biopolis and Fusionopolis as well as their immediate vicinity. A*STAR supports Singapore's key economic clusters by providing intellectual, human and industrial capital to its partners in industry. It also supports extramural research in the universities, and with other local and international partners. For more information about A*STAR, please visit http://www.a-star.edu.sg. About the Singapore Institute for Clinical Sciences (SICS) Established in 2007, the Singapore Institute for Clinical Sciences (SICS) is a research institute within the Agency for Science, Technology and Research (A*STAR), and its mission is to develop disease-oriented clinical and translational research programmes in key disease areas. SICS is distinguished by its focus on clinical sciences and the use of innovative approaches and technologies that enable the efficient and effective study of human health and diseases. The clinical scientists in SICS conduct the full spectrum of "bench to bedside" research activities in metabolic diseases (including diabetes, obesity and insulin resistance), pathways to normal growth and development (including cognitive and behavioural development), nutritional sciences as well as in certain viral infectious diseases such as chronic viral diseases. The institute aims to attract, train and nurture clinician-scientists and to develop joint programs with universities, academic medical centres, government hospitals and research institutes. For more information on SICS, please visit: http://www.sics.a-star.edu.sg

ELSE PRESS RELEASES FROM THIS DATE:

Smile!

2013-09-23

A brighter, better, longer-lasting dental implant may soon be on its way to your dentist's office. Dental implants are posts, usually made of titanium, that are surgically placed into the jawbone and topped with artificial teeth. More than dentures or bridges, implants mimic the look and feel of natural teeth. While most dental implants are successful, a small percentage fail and either fall out or must be removed. A scientist at Michigan Technological University wants to lower that rate to zero using nanotechnology. "Dental implants can greatly improve the lives of ...

Propofol discovery may help lead to development of new anesthetics

2013-09-23

New research on the most commonly used anaesthetic drug could help to unravel a long-standing mystery about how it induces a pain-free, sleep-like state. General anaesthetics are administered to tens of millions of people every year in hospitals, where they are used to sedate patients undergoing surgery. Despite this, scientists have yet to understand how the drug interacts with its targets in brain cells to achieve this effect. Following years of research on propofol, which has become the most commonly used anaesthetic since it was introduced in the 1980s, researchers ...

Immune system fights infection with performance enhancement

2013-09-23

Researchers in Melbourne, Australia, have found that even our immune system is subject to performance enhancement, with our bodies giving immune cells the boost they need to ensure the best team is selected to fight infections. The discovery could help in developing new treatments for blood diseases such as leukaemia and autoimmune diseases in which the body attacks its own tissues, such as in diabetes or rheumatoid arthritis. It could also be used to enhance immune response to HIV and other chronic infections. The finding, by researchers at the Walter and Eliza Hall ...

Climate change nothing new in Oz

2013-09-23

While we grapple with the impact of climate change, archaeologists suggest we spare a thought for Aboriginal Australians who had to cope with the last ice age. "The period scientists call the Last Glacial Maximum, or LGM for short, is the most significant climatic event ever faced by humans on this continent," Associate Professor Sean Ulm from James Cook University in Cairns said. Research recently published in the Journal of Archaeological Science sheds new light on the ways Aboriginal civilisation met the challenges of extreme climate change during the Last Glacial ...

Richness mapping and prediction of amphibians in Southern and Central China

2013-09-23

Systematic conservation planning is a multiple-objective process. Identification of important areas and species with high conservation priority is two of the research objectives. China is one of mega-biodiversity countries of the world. Along with rapid economic development and environmental degeneration, native and endemic species of China are confronting growing threats in the last two decades. It is an urgent agenda to set up relevant conservation policies, researches and decision supports so as to better reduce extinction risks of vertebrate animals of China. Amphibians ...

Encouraging outcomes for pediatric brain tumor patients treated with proton therapy

2013-09-23

Atlanta, September 22, 2013—When used to treat pediatric patients with intracranial malignant tumors, proton therapy may limit the toxicity of radiation therapy while preserving tumor control, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting. Typically, central nervous system malignancies are treated with surgical resection and post-operative radiation therapy. Proton therapy, an external beam radiation therapy in which protons deliver precise radiation doses to a tumor, offers significant sparing of ...

Sulfasalazine does not reduce diarrhea for patients receiving pelvic radiation therapy

2013-09-23

Atlanta, September 22, 2013—Patients receiving radiotherapy (RT) for cancers in the pelvic region can experience diarrhea, a negative side effect of radiation treatment. Sulfasalazine, an oral tablet used to treat inflammation of the bowels, had been shown in a past trial of 31 patients to decrease diarrhea during pelvic RT (Killic 2001). Sulfasalazine does not reduce diarrhea, according to research presented today at the American Society of Radiation Oncology's (ASTRO's) 55th Annual Meeting. The study also determined that the medication may be associated with a higher ...

Cisplatin combined with high-dose brachytherapy for advanced cervical cancer may be more beneficial

2013-09-23

Atlanta, September 22, 2013 — Adding the chemotherapy drug cisplatin to a treatment plan of radiation therapy (RT) and high-dose-rate brachytherapy (HDRB) for stage IIIB cervical cancer is beneficial, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting. The study also indicated that the combined treatments produced acceptable levels of toxicity. The randomized, controlled trial studied a total of 147 women in Brazil with stage IIIB squamous cell cervical cancer. A stage IIIB classification indicates that ...

Proton therapy is a cost-effective treatment for pediatric brain tumor patients

2013-09-23

Atlanta, September 22, 2013—Proton therapy, an external beam radiotherapy in which protons deliver precise radiation doses to a tumor and spare healthy organs and tissues, is cost-effective in treating medulloblastomas, fast-growing brain tumors that mainly affect children, when compared to standard photon radiation therapy, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting. The study used a first-order Monte Carlo simulation model to examine a population of 18-year old survivors of medulloblastoma brain ...

Adult cancer patients younger than 50 with limited brain mets have improved OS after SRS alone

2013-09-23

Atlanta, September 22, 2013—When treated with stereotactic radiosurgery (SRS), that is not combined with whole brain radiotherapy (WBRT), adult brain cancer patients who were 50 years old and younger were found to have improved survival, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting. Younger patients (under 50 years old) were also found to be at no greater risk of new brain metastases developing despite omission of WBRT. A highly advanced brain cancer treatment, stereotactic radiosurgery (SRS) utilizes ...

Patient heal thyself: Solution to treatment for chronic infections could lie in patient's blood

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: